written on 21.07.2017

PharmaBoardroom Releases New Mexico Pharma Report


PharmaBoardroom today releases its new 140-page Healthcare & Life Sciences Review Mexico 2017.

This report offers companies, investors, policymakers, and stakeholders crucial insight into the rich ecosystem of pharmaceuticals, biotech, and healthcare companies in Mexico, based on in-depth interviews conducted with leaders and pioneers across the value chain, from the secretary of health to heads of the various Mexican social security institutes, country managers of the world’s leading biopharmaceutical companies, and representatives from innovative local SMEs and service providers.

Healthcare & Life Sciences Review Mexico 2017 features sections on Mexico’s macroeconomic situation, healthcare, regulatory reform, pharma market, strategy, key therapeutic areas, manufacturing, clinical research, medtech, and logistics and distribution.


The report features in-depth interviews with:

Jose Narro Robles, Mexican secretary of health

Mikel Arriola, IMSS

Jose Reyes Baeza Terrazas, ISSSTE

Gabriel O’Shea, Seugor Popular

Julio Sanchez y Tepoz, COFEPRIS

Cristobal Thompson, AMIIF

Rafel Gual Cosio, CANIFARMA

Socorro Espana Lomeli, ANAFARM

Rodrigo Puga, Pfizer

Pedro Galvis, Merck


“From economic and demographic standpoints, Mexico continues to boast an excellent and stable macro-economic environment that should draw in the attention of any potential investor.”

Rafael Gual Cosio, CANIFARMA

“I deeply believe we can reach even greater health outcomes by better aligning the public and private sectors, which are truly complementary in our country.”

Jose Narro Robles, Secretary of Health

“Pharmaceutical investments in Mexico are growing faster than our production volume, while clinical trial activities, which represent high-added value investments, are the fastest growing investment segment of our industry.”

Alexis Serlin, Novartis & CANIFARMA

“80 percent of our health expenditure are used to treat only 20 percent of the Mexican population, affected by only three main illnesses: diabetes, cancer, and cardio-vascular diseases”

Mikel Arriola, IMSS

“COFEPRIS has been able to align its registration timelines with the best international standards, as market approvals are now granted within 60 working days.”

Julio Sanchez y Tepoz, COFEPRIS

Click here to register and download the report.